Hold with 30-35% trim at $28.12, structural stop at $27.00, hard $27.27 drift-tolerance trigger before Q3 binary
Hold rating is binding because all three Underweight triggers remain unactivated: (1) impairment-to-dividend linkage NOT activated despite $4B+ impairments, dividend paid with explicit management defense incentive; (2) 200 SMA break NOT activated, price at $28.12 is 9% above $25.79 200 SMA which remains intact as structural floor; (3) OCF coverage compression NOT activated, TTM FCF coverage is 1.12-1.28x with Q2 $302M print an artifact of $3.47-3.5B tax payment. Historical Hold calls averaged +0.2% to +0.9% alpha vs Underweight bleeding 50-80 bps per event. Trim is mandatory (passive Hold is a soft underweight) but 30-35% calibrated magnitude avoids over-committing ahead of binary Q3 catalyst where coiled setup could resolve either direction.
| Position | Action |
|---|---|
| Current position sizing | 30-35% tactical trim at $28.12 levels |
| Trim proceeds allocation | 2/3 rotate to MRK/JNJ via limit orders -2% to -3% from spot; 1/3 retained in cash/short-duration Treasuries at ~5% carry |
Pfizer at $28.12 is deeply undervalued on forward multiples (9.7x vs 12-15x peers), with non-cash impairments masking strong operational recovery ($3.5B Q2 2026 operating income, $25.7B normalized EBITDA), supporting a 6% dividend and asymmetric 2:1 to 3:1 risk/reward skewed to the upside as the stock coils for a catalyst-driven re-rating.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | $28.30 | bearish |
| 50 SMA | $27.26 | bullish |
| 200 SMA | $25.79 | bullish |
| RSI (14) | 53.55 | neutral |
| MACD Line | 0.304 | bearish |
| MACD Signal Line | 0.318 | bearish |
| MACD Histogram | -0.01 | bearish |
| ATR (14) | $0.50 | neutral |
| VWMA (20) | $28.01 | neutral |
| Bollinger Upper Band | $28.97 | bearish |
| Bollinger Middle Band | $28.06 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Pullback to $26.79-$27.50 with stabilizing RSI and management dividend-safety reassurance
Then: Consider adding to position
↩ rebuts: “Bears anchoring on GAAP losses”
EV: +$20% to +50% (re-rating to $34-$43) · concedes: Dividend coverage gap of ~7% is real; Impairments are real non-cash charges; Short-term momentum has cooled (MACD bearish cross); AI/risk-on rotation is a legitimate near-term headwind; FCF of $9.1B does not fully cover $9.77B dividend payout; Bear case scenario of $23-$25 (-14% to -18%) is possible if multiple things go wrong simultaneously
Pfizer is a mature post-rally consolidation at the top of its 52-week range that's about to give back gains as structural cracks widen — not a coiled spring waiting to fire higher.
· concedes: Q3 earnings in early November is a potential near-term catalyst that could provide a clean print (+3% to +7% to $29–$30); Dividend cut would be 'self-immolation' — management has incentive to avoid it; The 6% dividend yield does provide some carry if the stock chops sideways; FDA pipeline events could provide positive binary catalysts, though they are directional (not guaranteed up)
→ vs conservative: The 6% yield is a warning siren, not a gift; dividend is being funded by balance sheet drawdown, and yield-chasers become exit liquidity when the market prices in a dividend cut or freeze, which could drop the stock 15-25% in a single session
→ vs neutral: Above the 200 SMA is the lowest possible bar for bullishness; waiting for technical confirmation of a breakdown before acting means buying after the crash has already happened; the 50 SMA at $27.26 is the next logical test and if that fails, there is nothing between here and the low $25s except air
| neutral |
| Bollinger Lower Band | $27.15 | bullish |
Support: 27.95 · 27.26 · 27.15 · 25.79 | Resistance: 28.97 · 29.02 · 29.21
Pfizer (PFE) closed at $28.12 on 2026-10-01, trading near the middle Bollinger Band after rejecting the upper band at $28.97. The stock is in a structurally bullish long-term trend (price > 200 SMA > 50 SMA hierarchy), but short-term momentum has weakened with MACD completing a bearish crossover on 2026-09-23-24 (MACD 0.304 vs Signal 0.318) and RSI declining from overbought peaks of 77.36/73.95/72.36 to 53.55, forming bearish divergence versus the $29.21 September swing high. ATR compression at $0.50 (~1.8% of price) indicates a coiled market likely to experience volatility expansion. Key support zones are $27.95 (middle band), $27.26 (50 SMA), and $25.79 (200 SMA), while resistance sits at $28.97 (upper band) and $29.21 (swing high). A 5-10% pullback to retest the $27.00-$27.26 zone would offer a healthier risk/reward for new long entries, per the report's HOLD recommendation.
Market Capitalization
$160.27B
Enterprise Value
~$222.6B
Shares Outstanding
~5.69B
52-Week Range
$23.62 – $29.21
50-Day Moving Average
$27.21
200-Day Moving Average
$26.38
Beta
0.30
Dividend Yield
6.03%
Book Value per Share
$14.95
P/E (TTM)
37.0×
Forward P/E
9.7×
PEG Ratio
13.05
P/B Ratio
1.88×
Net Tangible Book Value
-$33.3B
Annual Dividend Rate
$1.72/share
Revenue (2025)
$62,579M
Revenue (TTM)
$63.7B
Gross Profit (2025)
$46,512M
Gross Margin (2025)
74.3%
Operating Income (2025)
$17,407M
Operating Margin (2025)
27.8%
Net Income (2025)
$7,771M
Diluted EPS (2025)
$1.36
Forward Consensus EPS
$2.90
R&D Expense (2025)
$10,437M
SG&A (2025)
$13,794M
D&A (2025)
$4,874M
EBITDA (reported, 2025)
$16,783M
EBITDA (normalized, 2025)
$25.7B
EBITDA Margin (reported)
26.9%
EBITDA Margin (normalized)
41.1%
Profit Margin (TTM)
6.8%
Net Margin (2025)
6.8%
ROE (TTM/2025)
5.0%
ROA (TTM/2025)
5.8%
FCF / Revenue
~15%
Total Assets (Jun 2026)
$201.1B
Cash & ST Investments (Jun 2026)
$11.7B
Total Debt (Jun 2026)
$63.2B
Net Debt (Jun 2026)
$62.2B
Stockholders' Equity (Jun 2026)
$85.2B
Goodwill + Intangibles (Jun 2026)
$118.5B
Net Tangible Assets (Jun 2026)
($33.3B)
Working Capital (Jun 2026)
$8.7B
Current Ratio (Jun 2026)
1.27
Debt/Equity
~0.73
Net Debt / EBITDA
~2.5×
Operating Cash Flow (2025)
$11.70B
CapEx (2025)
($2.63B)
Free Cash Flow (2025)
$9.08B
Dividends Paid (2025)
$9.77B
Acquisitions, net (2025)
($0.62B)
Ending Cash (2025)
$1.20B
Dividend Coverage (FCF basis)
<1.0×
Impairment Charges (Q4'25)
$4.47B
Impairment Charges (Q2'26)
$4.325B
Unusual Items (Q2'26)
($3.964B)
Interest Expense (approx.)
$9B
Q2'26 Revenue
$15,034M
Q2'26 Operating Income
$3,537M
Q2'26 Net Income
($248M)
Q2'26 Diluted EPS
($0.04)
Q2'26 Normalized EBITDA
$5.6B
Strengths
Concerns
Pfizer Inc. presents a classic earnings-recovery setup with forward P/E of 9.7× discounted vs. large-cap pharma peers at 12–15×, driven by artificially depressed TTM EPS ($0.76/$1.36 actual vs. $2.90 consensus) from massive non-cash impairment charges ($4B+ per quarter). The company's underlying operational strength is evidenced by normalized EBITDA of $25.7B (41.1% margin), 27.8% operating margin, and TTM revenue stability at $63.7B without COVID dependency. However, the 6.03% dividend yield—the primary equity attraction—is technically uncovered by FCF ($9.1B vs. $9.77B paid), creating dividend sustainability risk if the impairment cycle persists or patent cliffs materialize in the late 2020s.
Macro: Hawkish Fed stance with 97% probability of zero rate cuts in 2026 pushing 10-year Treasury to highest level since 2002; US recession odds at 8% and falling (-2pp w/w) signaling soft-landing base case; risk-on rotation into AI/tech names drawing capital away from defensives; no macro black swans in the news feed. Macro indicators (CPI, Core PCE, Fed Funds Rate, Unemployment) unavailable due to missing FRED API key.